Om P Mishra1, Ravindra Kumar2, Gopeshwar Narayan3, Pradeep Srivastava4, Abhishek Abhinay2, Rajniti Prasad2, Ankur Singh2, Vineeta V Batra5. 1. Division of Pediatric Nephrology, Department of Pediatrics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. opmpedia@yahoo.co.uk. 2. Division of Pediatric Nephrology, Department of Pediatrics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. 3. Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, India. 4. Department of Biochemical Engineering, Indian Institute of Technology, Banaras Hindu University, Varanasi, India. 5. Department of Pathology, G.B.Pant Hospital, New Delhi, India.
Abstract
BACKGROUND: The aims of this study were (1) to detect toll-like receptor (TLR)-3, TLR-4 and CD80 expression in peripheral blood mononuclear cells (PBMCs) and estimate urinary CD80 levels in children with idiopathic nephrotic syndrome and (2) to investigate the utility of these markers to differentiate between biopsy-proven minimal change disease (MCD) and focal segmental glomeruloscelerosis (FSGS). METHODS: The study included 70 patients with idiopathic nephrotic syndrome (NS), of whom 40 had steroid-sensitive NS (SSNS; 25 with active NS, 15 in remission) and 30 had steroid-resistant NS (SRNS) patients, and 23 healthy controls. TLR-3, TLR- 4 and CD80 mRNA expression levels in PBMCs were determined and the urinary CD80 level estimated. RESULTS: Median TLR-3, TLR-4 and CD80 mRNA expression levels were higher in patients with active SSNS than in those with SRNS, and the latter patient group also had significantly lower expression levels than the controls. The expression levels of these markers were associated with reductions in remission. Patients with biopsy-proven MCD had higher median expression levels of these markers than those with FSGS, but the differences were not statistically significant. Median urinary CD80/creatinine values were significantly higher in patients with SSNS and SRNS than in the controls and steroid-sensitive patients in remission (p < 0.001). CD80 levels were also significantly higher in patients with MCD than in those with FSGS (p = 0.002). A cut-off level of >914.5 ng/g had a sensitivity of 86.6%, specificity 71.4% and area under the curve of 0.828 (95% confidence interval 0.678-0.978, p = 0.002) for the diagnosis of MCD. CONCLUSIONS: Increased expressions of TLR-3, TLR-4 and CD80 mRNA and the level of urinary CD80/creatinine could be useful markers to differentiate patients of SSNS in relapse from those with SRNS. Further these markers can also distinguish biopsy proven MCD from FSGS in SRNS patients.
BACKGROUND: The aims of this study were (1) to detect toll-like receptor (TLR)-3, TLR-4 and CD80 expression in peripheral blood mononuclear cells (PBMCs) and estimate urinary CD80 levels in children with idiopathic nephrotic syndrome and (2) to investigate the utility of these markers to differentiate between biopsy-proven minimal change disease (MCD) and focal segmental glomeruloscelerosis (FSGS). METHODS: The study included 70 patients with idiopathic nephrotic syndrome (NS), of whom 40 had steroid-sensitive NS (SSNS; 25 with active NS, 15 in remission) and 30 had steroid-resistant NS (SRNS) patients, and 23 healthy controls. TLR-3, TLR- 4 and CD80 mRNA expression levels in PBMCs were determined and the urinary CD80 level estimated. RESULTS: Median TLR-3, TLR-4 and CD80 mRNA expression levels were higher in patients with active SSNS than in those with SRNS, and the latter patient group also had significantly lower expression levels than the controls. The expression levels of these markers were associated with reductions in remission. Patients with biopsy-proven MCD had higher median expression levels of these markers than those with FSGS, but the differences were not statistically significant. Median urinary CD80/creatinine values were significantly higher in patients with SSNS and SRNS than in the controls and steroid-sensitive patients in remission (p < 0.001). CD80 levels were also significantly higher in patients with MCD than in those with FSGS (p = 0.002). A cut-off level of >914.5 ng/g had a sensitivity of 86.6%, specificity 71.4% and area under the curve of 0.828 (95% confidence interval 0.678-0.978, p = 0.002) for the diagnosis of MCD. CONCLUSIONS: Increased expressions of TLR-3, TLR-4 and CD80 mRNA and the level of urinary CD80/creatinine could be useful markers to differentiate patients of SSNS in relapse from those with SRNS. Further these markers can also distinguish biopsy proven MCD from FSGS in SRNS patients.
Entities:
Keywords:
Biomarkers; CD 80; Children; Nephrotic syndrome; Toll like receptor-3; Toll like receptor-4
Authors: Eduardo H Garin; Wei Mu; John M Arthur; Christopher J Rivard; Carlos E Araya; Michiko Shimada; Richard J Johnson Journal: Kidney Int Date: 2010-05-19 Impact factor: 10.612
Authors: Tarak Srivastava; Mukut Sharma; Kok-Hooi Yew; Ram Sharma; R Scott Duncan; Moin A Saleem; Ellen T McCarthy; Alexander Kats; Patricia A Cudmore; Uri S Alon; Christopher J Harrison Journal: J Cell Commun Signal Date: 2012-11-17 Impact factor: 5.782
Authors: Debbie S Gipson; Susan F Massengill; Lynne Yao; Shashi Nagaraj; William E Smoyer; John D Mahan; Delbert Wigfall; Paul Miles; Leslie Powell; Jen-Jar Lin; Howard Trachtman; Larry A Greenbaum Journal: Pediatrics Date: 2009-07-27 Impact factor: 7.124
Authors: Michiko Shimada; Takuji Ishimoto; Pui Y Lee; Miguel A Lanaspa; Christopher J Rivard; Carlos A Roncal-Jimenez; David T Wymer; Hideaki Yamabe; Peter W Mathieson; Moin A Saleem; Eduardo H Garin; Richard J Johnson Journal: Nephrol Dial Transplant Date: 2011-05-26 Impact factor: 5.992
Authors: Gabriel Cara-Fuentes; Miguel A Lanaspa; Gabriela E Garcia; Mindy Banks; Eduardo H Garin; Richard J Johnson Journal: Pediatr Nephrol Date: 2018-03-01 Impact factor: 3.714
Authors: Howard Trachtman; Debbie S Gipson; Michael Somers; Cathie Spino; Sharon Adler; Lawrence Holzman; Jeffrey B Kopp; John Sedor; Sandra Overfield; Ayanbola Elegbe; Michael Maldonado; Anna Greka Journal: Kidney Int Rep Date: 2017-08-31